Knowledge of the involvement of the neurokinin substance P in emesis has led to the
development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of …

Книга «Эметический синдром (этиология, патогенез, профилактика и терапия)» вышла
в свет в 2005 г. Прошло 15 лет. За это время накопилось много материалов …

Recent years have witnessed significant improvements in the prevention and management
of chemotherapy-induced nausea and vomiting (CINV), allowing patients to complete their …

Although chemotherapeutic agents represent a cornerstone of cancer treatment,
chemotherapy-induced nausea and vomiting (CINV) affect the patients' quality of life and …

ABSTRACT Introduction: Five NK-1 RA formulations are commercially available to treat the
delayed phase of chemotherapy-induced nausea and vomiting (CINV) occurring between …

Background Rolapitant, a long-acting neurokinin (NK) 1 receptor antagonist (RA), has
demonstrated efficacy in prevention of chemotherapy-induced nausea and vomiting in …

Chemotherapy-induced nausea and vomiting (CINV) remains an important adverse effect of
cancer therapy. The goal of CINV prophylaxis is to reduce the morbidity associated with …

Breakthrough chemotherapy-induced nausea and vomiting (CINV) is nausea and/or
vomiting occurring within 5 days of chemotherapy administration despite using guideline …

Although antiemetic management in cancer therapy has improved, chemotherapy-induced
nausea and vomiting remain common and troubling adverse events. Chemotherapeutic …

Rolapitant is a selective, long‐acting neurokinin‐1 receptor antagonist, approved in the
United States and Europe for prevention of delayed chemotherapy‐induced nausea and …